Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiona Thomson

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Radiation Oncology (London, England)|August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Radiation Oncology (London, England)|December 3, 2021
Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 11, 2021
Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural DiseasesSelina Tsim, Laura Alexander, Caroline Kelly, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2010
Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonistAngus R Brown, Michael Bosies, Helen Cameron, et al.
Thorax|May 8, 2026
Impact of a national mesothelioma network on outcomes including survivalMatthew Tate, Joshua Joseph Roche, Selina Tsim, et al.
Journal of Medicinal Chemistry|February 27, 2020
Discovery of [<sup>11</sup>C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative DiseasesLing Tong, Wenping Li, Michael Man-Chu Lo, et al.
BMJ (Clinical Research Ed.)|December 11, 2013
Children must be protected from the tobacco industry's marketing tacticsNicholas Hopkinson, Colin Wallis, Bernard Higgins, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Radiation Oncology (London, England)|August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Radiation Oncology (London, England)|December 3, 2021
Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 11, 2021
Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural DiseasesSelina Tsim, Laura Alexander, Caroline Kelly, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2010
Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonistAngus R Brown, Michael Bosies, Helen Cameron, et al.
Thorax|May 8, 2026
Impact of a national mesothelioma network on outcomes including survivalMatthew Tate, Joshua Joseph Roche, Selina Tsim, et al.
Journal of Medicinal Chemistry|February 27, 2020
Discovery of [<sup>11</sup>C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative DiseasesLing Tong, Wenping Li, Michael Man-Chu Lo, et al.
BMJ (Clinical Research Ed.)|December 11, 2013
Children must be protected from the tobacco industry's marketing tacticsNicholas Hopkinson, Colin Wallis, Bernard Higgins, et al.
Pageof 4